Brought to you by 
All that Jazz: biggest biotech venture round ever
29 Mar 2004
Executive Summary
Jazz Pharmaceuticals, started up last year by a group of former Alza people, raised an astonishing $250mm in its Series B financing. The company's strategy is to in-license a portfolio of known compounds in the neurology and psychiatry fields that it can improve or develop for new uses.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
All that Jazz: biggest biotech venture round ever
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice